Title : Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases.

Pub. Date : 2022 Jan 1

PMID : 34261918






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases. osimertinib epidermal growth factor receptor Homo sapiens
2 Here, we describe osimertinib as an effective therapy for EGFR-KDD positive lung adenocarcinoma and thereby provide a new alternative for further treatment following resistance to first- and second-generation EGFR-TKIs. osimertinib epidermal growth factor receptor Homo sapiens
3 Here, we describe osimertinib as an effective therapy for EGFR-KDD positive lung adenocarcinoma and thereby provide a new alternative for further treatment following resistance to first- and second-generation EGFR-TKIs. osimertinib epidermal growth factor receptor Homo sapiens